Breastfeeding and circulating immunological markers during the first 3 years of life: the DIABIMMUNE study

• Published in: Diabetologia
• Main Authors: Miettinen, Maija E., Honkanen, Jarno, Niinistö, Sari, Vaarala, Outi, Virtanen, Suvi M., Knip, Mikael
• Other Authors: The liv och hälsa fund, Centre of Excellence in Molecular Systems Immunology and Physiology Research, Seventh Framework Programme, Suomen Akatemia, European Foundation for the Study of Diabetes
• Format: Article in Journal/Newspaper
• Language: English
• Published: Springer Science and Business Media LLC 2021
• Subjects: Endocrinology, Diabetes and Metabolism; Internal Medicine; karelian
• Online Access: http://dx.doi.org/10.1007/s00125-021-05612-2; https://link.springer.com/content/pdf/10.1007/s00125-021-05612-2.pdf; https://link.springer.com/article/10.1007/s00125-021-05612-2/fulltext.html

Abstract Aims/hypothesis Our aim was to study the association between duration of breastfeeding and circulating immunological markers during the first 3 years of life in children with HLA-conferred susceptibility to type 1 diabetes. Methods We performed a longitudinal analysis of 38 circulating immunological markers (cytokines, chemokines and growth factors) in serum samples from Finnish (56 individuals, 147 samples), Estonian (56 individuals 148 samples) and Russian Karelian children (62 individuals, 149 samples) at 3, 6, 12, 18, 24 and 36 months of age. We also analysed gut inflammation markers (calprotectin and human β defensin-2) at 3 ( n = 96) and 6 months ( n = 153) of age. Comparisons of immunological marker medians were performed between children who were breastfed for 6 months or longer vs children who were breastfed for less than 6 months. Results Breastfeeding for 6 months or longer vs less than 6 months was associated with lower median of serum immunological markers at 6 months (granulocyte-macrophage colony-stimulating factor [GMCSF], macrophage inflammatory protein [MIP-3α]), 12 months (IFN-α2, vascular endothelial growth factor, GMCSF, IFN-γ, IL-21), 18 months (FGF-2, IFN-α2) and 24 months of age (CCL11 [eotaxin], monocyte chemoattractant protein-1, TGFα, soluble CD40 ligand, IL-13, IL-21, IL-5, MIP-1α) (all p < 0.01) but not at 36 months of age. Breastfeeding was not associated with gut inflammation markers at 3 and 6 months of age. Conclusions/interpretation Children who were breastfed for 6 months or longer had lower medians for 14 immunological markers at one or more age points during the first 2 years of life compared with children who were breastfed for less than 6 months. The clinical meaning of the findings is not clear. However, the present study contributes to the understanding of immunological differences in children that have been breastfed longer, and thus provides a mechanistic suggestion for the previously observed associations between breastfeeding and risk of type 1 diabetes. Graphical abstract